MarketPulse

commercial launch

5 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Olema Oncology Advances Breast Cancer Pipeline, Secures $218.5M in Funding

Olema reported strong trial progress for palazestrant in breast cancer, raised $218.5M, and expects pivotal data in fall 2026.
PFEOLMAPhase 3 trialsclinical development
The Motley FoolThe Motley Fool··Sara Appino

Cytokinetics Executive Cashes In $929K Options as Cardiac Drug Launches

Cytokinetics insider Andrew Callos sold $929K in stock options weeks after FDA approval of heart drug myqorzo, reducing holdings by 23%.
CYTKFDA approvalbiotech
BenzingaBenzinga··Vandana Singh

OneMedNet Launches AI Platform Despite 11.5% Stock Decline

$ONMD drops 11.5% after announcing AI-powered clinical data platform launch serving 2,130 healthcare sites with subscription model.
PLTRONMDONMDWcommercial launchpenny stock
GlobeNewswire Inc.GlobeNewswire Inc.··Mesoblast Limited

Mesoblast Posts Strong H1 Results on Ryoncil® Commercial Traction

Mesoblast reports strong H1 results with Ryoncil® revenue of $51.3M and narrowed net losses. Commercial expansion underway with 49 transplant centers operational and FY2026 guidance of $110-120M revenue.
MESOfinancial resultsFDA approval
GlobeNewswire Inc.GlobeNewswire Inc.··Cytokinetics, Incorporated

Cytokinetics Launches MYQORZO Following FDA Approval, Guides 2026 Spending

Cytokinetics launches MYQORZO for heart disease post-FDA approval; guides $830-870M spending in 2026 with strong cash position supporting commercial expansion.
SNYBAYRYCYTKFDA approvalclinical trials